GSK's Nucala Shows Positive Results in Phase III COPD Trial

Sep 6, 2024, 07:56 AM

GSK's asthma drug Nucala has shown positive results in a phase III late-stage trial for treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs. The British drugmaker announced on Friday that Nucala met the main goal of the trial, potentially opening up a new avenue of growth for the medicine. This development comes after an FDA rejection in 2018, and GSK is now preparing to file Nucala for COPD again, armed with the new phase III data. The trial results indicate that the drug can reduce COPD attacks, which may benefit patients with this chronic lung condition.